Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvaliase in Adolescent Subjects With Phenylketonuria
NCT05270837Phase 3Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Jan 2025
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of pegvaliase in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Started Jun 2022; status: active, not recruiting.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT05270837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270837.